MRNA Moderna

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of mRNA-based vaccines and therapeutics across infectious diseases, oncology, and rare diseases
• • New product: Launch of mNEXSPIKE COVID vaccine in Q3 2025, now leading US retail product; ongoing filings for flu+COVID and flu-only vaccines in multiple regions
• • Strategic shift: Geographic expansion with three new Moderna-managed manufacturing sites in UK, Canada, Australia; partnership with Recordati for rare disease mRNA-3927 development
• • Quantitative metric: 2025 revenue $1.9B, primarily from COVID vaccines; eight Phase 2/3 oncology trials on intismeran autogene in collaboration with Merck underway
• • Noteworthy fact: First FDA acceptance of amended BLA for seasonal flu vaccine (mRNA-1010) with PDUFA date August 5, 2026, after Type A meeting and revised regulatory pathway

Risk Factors

• • Regulatory risk: FDA refusal-to-file letter on seasonal flu vaccine mRNA-1010; amended BLA accepted with PDUFA date August 5, 2026
• • Geopolitical risk: COVID and RSV vaccine manufacturing now onshored in US, Australia, UK, and Canada under government agreements for local supply and pandemic preparedness
• • Operational risk: mRNA-1010 flu vaccine regulatory review delays following FDA Type A meeting and need for additional study in older adults
• • Competitive risk: Collaboration with Merck on intismeran autogene (mRNA-4157) immunotherapy facing competition from other checkpoint inhibitors like KEYTRUDA
• • Financial risk: $1.5 billion five-year credit facility entered November 2025, including $600 million funded initial term loan, adding leverage and interest expense burden

Management Discussion & Analysis

• • Revenue $1.944B, down 40% YoY ($3.236B in 2024); net product sales $1.818B, down 42% YoY ($3.109B in 2024) due to lower COVID vaccine demand
• • Operating loss $3.074B vs $3.945B; cost of sales $868M (48% of net product sales) vs $1.464B (47%); R&D $3.132B down 31%, SG&A $1.018B down 13%
• • Best segment: Other revenue stable at $126M; worst segment: Net product sales down $1.29B driven by COVID vaccine decline
• • Net cash used in operations $1.873B (improved from $3.004B); capex $192M; financing proceeds $593M including $578M credit facility draw; cash & investments $8.135B down 15%
• • Management expects product sales growth in 2026 from strategic partnerships and mNEXSPIKE uptake; anticipates modest R&D reductions and stable SG&A; identifies COVID market decline as ongoing risk

What are the latest MRNA SEC filings in 2026?

Moderna (MRNA) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on May 1, 2026, an 8-K current report on July 31, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MRNA file its most recent 10-K annual report?

Moderna (MRNA) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MRNA 10-Q quarterly reports?

Moderna (MRNA)'s most recent 10-Q quarterly report was filed on May 1, 2026. SignalX displays every MRNA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MRNA filed recently?

Moderna (MRNA)'s most recent 8-K was filed on July 31, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MRNA insider trading activity (Form 4)?

SignalX aggregates every MRNA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MRNA file with the SEC?

Moderna (MRNA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MRNA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Moderna (MRNA).

What is MRNA's SEC CIK number?

Moderna (MRNA)'s SEC CIK (Central Index Key) number is 1682852. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1682852 to look up all MRNA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MRNA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Moderna (MRNA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.